Kymera Therapeutics to Participate in Upcoming February Investor Conferences
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; and
- Oppenheimer 35th Annual Healthcare Life Sciences Conference held virtually on February 11 at 11:20 a.m. ET.
Live webcasts of the presentations will be available under “” in the Investors section of the Company’s website at . Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on or .
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
857-285-5300
